International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson’s Disease Clinical Trial

CARLSBAD, CA – International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the positive six months interim results of the first cohort of Parkinson’s disease (PD) patients receiving 30 million ISC-hpNSC cells in the ongoing clinical study. All patients in the first cohort […]